

* * * * * Welcome to STN International * * * * *

<u>NEWS 1</u>		Web Page URLs for STN Seminar Schedule - N. America
<u>NEWS 2</u>		"Ask CAS" for self-help around the clock
<u>NEWS 3</u>	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
<u>NEWS 4</u>	FEB 28	BABS - Current-awareness alerts (SDIs) available
<u>NEWS 5</u>	MAR 02	GBFULL: New full-text patent database on STN
<u>NEWS 6</u>	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
<u>NEWS 7</u>	MAR 03	MEDLINE file segment of TOXCENTER reloaded
<u>NEWS 8</u>	MAR 22	KOREAPAT now updated monthly; patent information enhanced
<u>NEWS 9</u>	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
<u>NEWS 10</u>	MAR 22	PATDPASPC - New patent database available
<u>NEWS 11</u>	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
<u>NEWS 12</u>	APR 04	EPFULL enhanced with additional patent information and new fields
<u>NEWS 13</u>	APR 04	EMBASE - Database reloaded and enhanced
<u>NEWS 14</u>	APR 18	New CAS Information Use Policies available online
<u>NEWS 15</u>	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
<u>NEWS 16</u>	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
<u>NEWS 17</u>	MAY 23	GBFULL enhanced with patent drawing images
<u>NEWS 18</u>	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
<u>NEWS 19</u>	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
<u>NEWS 20</u>	JUN 13	RUSSIAPAT: New full-text patent database on STN
<u>NEWS 21</u>	JUN 13	FRFULL enhanced with patent drawing images
<u>NEWS 22</u>	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
<u>NEWS 23</u>	JUL 01	MEDICONF removed from STN
<u>NEWS 24</u>	JUL 07	STN Patent Forums to be held in July 2005
<u>NEWS 25</u>	JUL 13	SCISEARCH reloaded
<u>NEWS 26</u>	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
<u>NEWS EXPRESS</u>		JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
<u>NEWS HOURS</u>		STN Operating Hours Plus Help Desk Availability
<u>NEWS INTER</u>		General Internet Information
<u>NEWS LOGIN</u>		Welcome Banner and News Items
<u>NEWS PHONE</u>		Direct Dial and Telecommunication Network Access to STN
<u>NEWS WWW</u>		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:58:50 ON 10 AUG 2005

=> file uspatall

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'USPATFULL' ENTERED AT 18:59:06 ON 10 AUG 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:59:06 ON 10 AUG 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> a maclean d/in

E1	1	MACLEAN CRAIG I/IN
E2	2	MACLEAN CRAWFORD JAMIESON WILLIAM/IN
E3	0 -->	MACLEAN D/IN
E4	1	MACLEAN DANIEL S/IN
E5	5	MACLEAN DAVID/IN
E6	26	MACLEAN DAVID B/IN
E7	1	MACLEAN DAVID R/IN
E8	1	MACLEAN DAVID S/IN
E9	4	MACLEAN DEREK/IN
E10	42	MACLEAN DONALD L/IN
E11	1	MACLEAN DONALD R/IN
E12	3	MACLEAN DOUG/IN

=> s a6

L1 26 "MACLEAN DAVID B"/IN

=> d 1-26

L1 ANSWER 1 OF 26 USPATFULL on STN

Full
Text

Citing
References

AN 2005:171876 USPATFULL

TI Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions

IN **MacLean, David B.**, Providence, RI, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES

PA Pfizer Inc (U.S. corporation)

PI US 2005148625 A1 20050707

AI US 2005-71955 A1 20050303 (11)

RLI Division of Ser. No. US 2002-133006, filed on 26 Apr 2002, PENDING
Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, GRANTED, Pat.
No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb
2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733,
filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331

PRAI US 1996-13212P 19960228 (60)

DT Utility

FS APPLICATION

LN.CNT 1986

INCL INCLM: 514/310.000
INCLS: 514/319.000; 514/343.000; 514/408.000

NCL NCLM: 514/310.000
NCLS: 514/319.000; 514/343.000; 514/408.000

IC [7]
ICM: A61K031-4709
ICS: A61K031-454; A61K031-4439; A61K031-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 26 USPATFULL on STN

Full Text	Chngg References

AN 2004:159258 USPATFULL
 TI Use of growth hormone secretagogues for treatment of physical performance decline
 IN **MacLean, David B.**, Providence, RI, UNITED STATES
 Landschulz, William H., East Lyme, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2004122062 A1 20040624
 AI US 2003-720977 A1 20031124 (10)
 RLI Continuation of Ser. No. US 2001-892702, filed on 27 Jun 2001, ABANDONED
 PRAI US 2000-214980P 20000629 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1967
 INCL INCLM: 514/355.000
 INCLS: 514/423.000
 NCL NCLM: 514/355.000
 NCLS: 514/423.000
 IC [7]
 ICM: A61K031-44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 26 USPATFULL on STN

Full Text	Chngg References

AN 2004:13471 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions
 IN **MacLean, David B.**, Providence, RI, UNITED STATES
 Thompson, David D., Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc. (U.S. corporation)
 PI US 2004009994 A1 20040115
 AI US 2003-615282 A1 20030707 (10)
 RLI Division of Ser. No. US 2001-999291, filed on 15 Nov 2001, GRANTED, Pat. No. US 6613796 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2058
 INCL INCLM: 514/266.200
 INCLS: 514/266.220; 514/256.000; 514/307.000; 514/314.000
 NCL NCLM: 514/266.200
 NCLS: 514/256.000; 514/266.220; 514/307.000; 514/314.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-506; A61K031-4709
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 26 USPATFULL on STN

Full Text	Chngg References

AN 2003:312744 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
 IN **MacLean, David B.**, Providence, RI, UNITED STATES

Thompson, David D., Gales Ferry, CT; UNITED STATES

PI US 2003220349 A1 20031127
US 6911456 B2 20050628
 AI US 2002-133006 A1 20020426 (10)
 RLI Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, GRANTED, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2038
 INCL INCLM: 514/256.000
 INCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000; 514/394.000; 514/415.000
 NCL NCLM: 514/315.000
 NCL NCLM: 514/256.000
 NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000; 514/394.000; 514/415.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-506; A61K031-4709; A61K031-4184; A61K031-4439; A61K031-404
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:214288 USPATFULL
 TI Therapy for andropause using estrogen agonists / antagonists and testosterone
 IN **MacLean, David B.**, Providence, RI, UNITED STATES
 PI US 2002115676 A1 20020822
 AI US 2001-995130 A1 20011127 (9)
 PRAI US 2000-250071P 20001130 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2692
 INCL INCLM: 514/266.200
 INCLS: 514/256.000; 514/314.000; 514/277.000
 NCL NCLM: 514/266.200
 NCLS: 514/256.000; 514/277.000; 514/314.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-505; A61K031-506
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:179201 USPATFULL
 TI Intermittent administration of a growth hormone secretagogue
 IN **MacLean, David B.**, Providence, RI, UNITED STATES
 PI US 2002094992 A1 20020718
 AI US 2001-940165 A1 20010827 (9)
 PRAI US 2000-229077P 20000830 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2898
 INCL INCLM: 514/303.000
 NCL NCLM: 514/303.000

IC [7]
 ICM: A61K031-4745
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 26 USPATFULL on STN

Full Text	Citing References
AN	2002:172363 USPATFULL
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
IN	MacLean, David B. , Providence, RI, UNITED STATES Thompson, David D., Gales Ferry, CT, UNITED STATES
PI	US 2002091121 A1 20020711 US 6613796 B2 20030902
AI	US 2001-999291 A1 20011115 (9)
RLI	Division of Ser. No. <u>US 2000-511806</u> , filed on 23 Feb 2000, PATENTED Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, PATENTED
PRAI	<u>US 1996-13212P</u> 19960228 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2060
INCL	INCLM: 514/217.010 INCLS: 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000
NCL	NCLM: 514/428.000
NCL	NCLM: 514/217.010 NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000

IC [7]
 ICM: A61K031-55
 ICS: A61K031-5513; A61K031-517; A61K031-506; A61K031-4709
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 8 OF 26 USPATFULL on STN

Full Text	Citing References
AN	2002:51000 USPATFULL
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
IN	Maclean, David B. , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer, Inc., New York, NY, United States (U.S. corporation)
PI	US 6355670 B1 20020312
AI	US 2000-511806 20000223 (9)
RLI	Continuation of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997
PRAI	<u>US 1996-13212P</u> 19960228 (60)
DT	Utility
FS	GRANTED
LN.CNT	2011
INCL	INCLM: 514/428.000 INCLS: 514/343.000; 514/319.000
NCL	NCLM: 514/428.000 NCLS: 514/319.000; 514/343.000

IC [7]
 ICM: A61K031-40
 ICS: A61K031-44; A61K031-445
 EXF 514/319; 514/428; 514/343
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 9 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:48646 USPATFULL
 TI Use of growth hormone secretagogues for treatment of physical performance decline
 IN **MacLean, David B.**, Providence, RI, UNITED STATES
 Landschulz, William H., East Lyme, CT, UNITED STATES
 PI US 2002028838 A1 20020307
 AI US 2001-892702 A1 20010627 (9)
 PRAI US 2000-214980P 20000629 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1964
 INCL INCLM: 514/354.000
 INCLS: 514/423.000; 514/255.060
 NCL NCLM: 514/354.000
 NCLS: 514/255.060; 514/423.000
 IC [7]
 ICM: A61K031-497
 ICS: A61K031-44; A61K031-401
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 10 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:145314 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
 IN **Maclean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PI US 2001018451 A1 20010830
US 6403611 B2 20020611
 AI US 2001-803516 A1 20010309 (9)
 RLI Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, PENDING
 Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED,
 Pat. No. US 6107331
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2063
 INCL INCLM: 514/428.000
 INCLS: 514/320.000; 514/304.000
 NCL NCLM: 514/315.000
 NCL NCLM: 514/428.000
 NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000
 IC [7]
 ICM: A61K031-445
 ICS: A61K031-46
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 11 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:131333 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
 IN **MacLean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 6274618 B1 20010814

AI US 1999-314758 19990519 (9)
RLI Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, now
 patented, Pat. No. US 6107331
PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1933
 INCL INCLM: 514/428.000
 INCLS: 514/213.000; 514/317.000; 514/331.000
 NCL NCLM: 514/428.000
 NCLS: 514/317.000; 514/331.000
 IC [7]
 ICM: A61K031-40
 ICS: A01N043-36
 EXF 514/317; 514/213; 514/331; 514/428
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 12 OF 26 USPATFULL on STN

Full Text	References
AN	2000:109836 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting
 pathological conditions
 IN **MacLean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6107331 20000822
AI US 1997-803733 19970221 (8)
PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 1927
 INCL INCLM: 514/428.000
 INCLS: 514/427.000
 NCL NCLM: 514/428.000
 NCLS: 514/427.000
 IC [7]
 ICM: A61K031-40
 EXF 514/427; 514/428
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 26 USPATFULL on STN

Full Text	References
AN	2000:102333 USPATFULL

TI Combination therapy to treat osteoporosis-polyphosphonates and estrogen
 agonists
 IN **Maclean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6100301 20000808
AI US 1998-92100 19980605 (9)
PRAI US 1996-12409P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 743
 INCL INCLM: 514/648.000
 INCLS: 514/012.000
 NCL NCLM: 514/648.000
 NCLS: 514/012.000

IC [7]
 ICM: A61K031-135
 ICS: A61K038-00
 EXF 514/648; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 14 OF 26 USPATFULL on STN

	Full Text	Citing References
AN	2000:54092	USPATFULL
TI	Combination therapy to prevent bone loss-progesterone and estrogen agonists	
IN	MacLean, David B. , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States	
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)	
PI	US 6057309	20000502
AI	US 1998-193265	19981116 (9)
RLI	Continuation of Ser. No. <u>US 1997-803710</u> , filed on 21 Feb 1997, now abandoned	
PRAI	US 1996-12400P	19960228 (60)
DT	Utility	
FS	Granted	
LN.CNT	438	
INCL	INCLM: 514/171.000 INCLS: 514/648.000	
NCL	NCLM: 514/171.000 NCLS: 514/648.000	
IC	[7] ICM: A61K031-56 ICS: A61K031-135	
EXF	514/648; 514/171	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 15 OF 26 USPATFULL on STN

	Full Text	Citing References
AN	2000:9953	USPATFULL
TI	Method of increasing testosterone	
IN	MacLean, David B. , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States	
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)	
PI	US 6017964	20000125
AI	US 1998-208729	19981209 (9)
RLI	Continuation of Ser. No. <u>US 1997-803711</u> , filed on 21 Feb 1997, now abandoned	
PRAI	US 1996-21181P	19960228 (60)
DT	Utility	
FS	Granted	
LN.CNT	348	
INCL	INCLM: 514/648.000	
NCL	NCLM: 514/648.000	
IC	[6] ICM: A61K031-135	
EXF	514/648	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L1 ANSWER 16 OF 26 USPATFULL on STN

	Full Text	Citing References
AN	1999:146631	USPATFULL

TI Inhibition of autoimmune diseases
 IN **MacLean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 5985932 19991116
AI US 1997-804346 19970221 (8)
PRAI US 1996-12402P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 392
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 17 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1999:40459 USPATFULL
 TI Method of treating diseases and conditions with estrogen agonists and antagonists
 IN **MacLean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5889042 19990330
AI US 1997-803706 19970221 (8)
PRAI US 1996-13213P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 1668
 INCL INCLM: 514/127.000
 NCL NCLM: 514/427.000
 IC [6]
 ICM: A61K031-40
 EXF 514/427
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 18 OF 26 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1999:7425 USPATFULL
 TI Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists
 IN **MacLean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5861438 19990119
AI US 1997-803712 19970221 (8)
PRAI US 1996-12399P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 530
 INCL INCLM: 514/648.000
 INCLS: 514/012.000
 NCL NCLM: 514/648.000
 NCLS: 514/012.000
 IC [6]
 ICM: A61K038-00

ICS: A61K031-135
 EXF 514/12; 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 19 OF 26 USPATFULL on STN

Full Text	Citing References
AN	1998:75623 USPATFULL
TI	Combination therapy to treat osteoporosis - polyphosphonates and estrogen agonists
IN	MacLean, David B. , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 5773477 19980630
AI	US 1997-803707 19970221 (8)
PRAI	US 1996-12409P 19960228 (60)
DT	Utility
FS	Granted
LN.CNT	499
INCL	INCLM: 514/648.000 INCLS: 514/102.000; 514/108.000
NCL	NCLM: 514/648.000 NCLS: 514/102.000; 514/108.000
IC	[6] ICM: A61K031-135 ICS: A61K031-66
EXF	514/648; 514/102; 514/108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L1 ANSWER 20 OF 26 USPATFULL on STN

Full Text	Citing References
AN	1998:33959 USPATFULL
TI	Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IN	MacLean, David B. , Providence County, RI, United States Thompson, David D., New London County, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 5733937 19980331
AI	US 1997-804702 19970221 (8)
PRAI	US 1996-12410P 19960228 (60)
DT	Utility
FS	Granted
LN.CNT	363
INCL	INCLM: 514/648.000
NCL	NCLM: 514/648.000
IC	[6] ICM: A61K031-135
EXF	514/648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L1 ANSWER 21 OF 26 USPATFULL on STN

Full Text	Citing References
AN	1998:25261 USPATFULL
TI	Protection of ischemic myocardium against reperfusion damage
IN	MacLean, David B. , Groton, CT, United States Thompson, David D., Groton, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 5726207 19980310

AI US 1997-805040 19970221 (8)
 PRAI US 1996-12401P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 303
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/646
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 22 OF 26 USPATFULL on STN

Full
 Text

AN 1998:17354 USPATFULL
 TI 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
 IN **Maclean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5719191 19980217
 AI US 1997-805039 19970221 (8)
 PRAI US 1996-25201P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 424
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 23 OF 26 USPATFULL on STN

Full
 Text

AN 1998:17353 USPATFULL
 TI Inhibition of myeloperoxidase activity
 IN **MacLean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5719190 19980217
 AI US 1997-803709 19970221 (8)
 PRAI US 1986-12403P 19860228 (60)
 DT Utility
 FS Granted
 LN.CNT 362
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 24 OF 26 USPAT2 on STN

Full
 Text

AN 2003:312744 USPAT2
 TI Use of estrogen antagonists and estrogen agonists in inhibiting
 pathological conditions

IN **MacLean, David B.**, Providence, RI, UNITED STATES
 Thompson, David D., Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc, New York, NY, UNITED STATES (U.S. corporation)
 PI US 6911456 B2 20050628
 AI US 2002-133006 20020426 (10)
 RLI Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, Pat. No. US 6107331
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2014
 INCL INCLM: 514/315.000
 INCLS: 514/428.000; 514/429.000
 NCL NCLM: 514/315.000
 NCL NCLM: 514/256.000
 NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000; 514/394.000; 514/415.000
 IC [7]
 ICM: A61K031-445
 EXF 514/315; 514/428; 514/429
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 25 OF 26 USPAT2 on STN

Full Text	Citing References
AN	2002:172363 USPAT2
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
IN	Maclean, David B. , Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	<u>US 6613796</u> B2 20030902
AI	<u>US 2001-999291</u> 20011115 (9)
RLI	Division of Ser. No. <u>US 2000-511806</u> , filed on 3 Feb 2000, now patented, Pat. No. <u>US 6355670</u> Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, now patented, Pat. No. <u>US 6107331</u>
PRAI	<u>US 1996-13212P</u> 19960228 (60)
DT	Utility
FS	GRANTED
LN.CNT	2003
INCL	INCLM: 514/428.000 INCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000
NCL	NCLM: 514/428.000
NCL	NCLM: 514/217.010 NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000
IC	[7] ICM: A61K031-40 ICS: A61K031-445; A61K031-44
EXF	514/428; 514/429; 514/343; 514/319; 514/315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L1 ANSWER 26 OF 26 USPAT2 on STN

Full Text	Citing References
AN	2001:145314 USPAT2
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN **Maclean, David B.**, Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6403611 B2 20020611
 AI US 2001-803516 20010309 (9)
 RLI Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, now
 patented, Pat. No. US 6274618 Continuation of Ser. No. US 1997-803733,
 filed on 21 Feb 1997, now patented, Pat. No. US 6107331
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2014
 INCL INCLM: 514/315.000
 INCLS: 514/428.000; 514/429.000
 NCL NCLM: 514/315.000
 NCL NCLM: 514/428.000
 NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000
 IC [7]
 ICM: A61K031-445
 EXF 514/429; 514/428; 514/315
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> @ thompson d/in

E1	2	THOMPSON CYNTHIA W/IN
E2	6	THOMPSON CYRIL V/IN
E3	0 -->	THOMPSON D/IN
E4	1	THOMPSON D F TOMMY/IN
E5	6	THOMPSON D SCOTT/IN
E6	1	THOMPSON DACID A/IN
E7	1	THOMPSON DALE E/IN
E8	4	THOMPSON DALE F/IN
E9	2	THOMPSON DALE G/IN
E10	1	THOMPSON DALE J/IN
E11	1	THOMPSON DALLAS A/IN
E12	1	THOMPSON DALLAS GLEN/IN

=> @

E13	2	THOMPSON DALTON/IN
E14	1	THOMPSON DAN/IN
E15	4	THOMPSON DANIEL/IN
E16	2	THOMPSON DANIEL A/IN
E17	2	THOMPSON DANIEL E/IN
E18	4	THOMPSON DANIEL G/IN
E19	2	THOMPSON DANIEL GEORGE/IN
E20	9	THOMPSON DANIEL J/IN
E21	11	THOMPSON DANIEL L/IN
E22	11	THOMPSON DANIEL LEE/IN
E23	2	THOMPSON DANIEL MARK/IN
E24	1	THOMPSON DANIEL P/IN

=> @

E25	2	THOMPSON DANIEL R/IN
E26	1	THOMPSON DANIEL SCOTT/IN
E27	34	THOMPSON DANIEL T/IN
E28	3	THOMPSON DANIEL W/IN
E29	1	THOMPSON DANNA D/IN
E30	2	THOMPSON DANNY B/IN
E31	5	THOMPSON DANNY C/IN
E32	2	THOMPSON DANNY CHARLES/IN

E33 7 THOMPSON DANNY L/IN
 E34 10 THOMPSON DANNY R/IN
 E35 1 THOMPSON DANNY W/IN
 E36 2 THOMPSON DARRELL/IN

=> e

E37 1 THOMPSON DARRELL D/IN
 E38 2 THOMPSON DARRELL L/IN
 E39 13 THOMPSON DARRELL R/IN
 E40 3 THOMPSON DARRELL T/IN
 E41 2 THOMPSON DARREN/IN
 E42 10 THOMPSON DARREN M/IN
 E43 1 THOMPSON DARROW/IN
 E44 2 THOMPSON DARROW D/IN
 E45 2 THOMPSON DARYL L/IN
 E46 1 THOMPSON DAVE/IN
 E47 47 THOMPSON DAVID/IN
 E48 65 THOMPSON DAVID A/IN

=> e

E49 4 THOMPSON DAVID ALLEN/IN
 E50 6 THOMPSON DAVID B/IN
 E51 9 THOMPSON DAVID C/IN
 E52 3 THOMPSON DAVID CHARLES/IN
 E53 1 THOMPSON DAVID CLYDE/IN
 E54 78 THOMPSON DAVID D/IN
 E55 6 THOMPSON DAVID E/IN
 E56 2 THOMPSON DAVID EUGENE/IN
 E57 27 THOMPSON DAVID F/IN
 E58 1 THOMPSON DAVID FRANCIS/IN
 E59 11 THOMPSON DAVID G/IN
 E60 1 THOMPSON DAVID GALE/IN

=> * e54

L2 78 "THOMPSON DAVID D"/IN

=> d 1-78

L2 ANSWER 1 OF 78 USPATFULL on STN

Full
Text

Chng
References

AN 2005:171876 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists inhibiting
 pathological conditions
 IN MacLean, David B., Providence, RI, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005148625 A1 20050707
 AI US 2005-71955 A1 20050303 (11)
 RLI Division of Ser. No. US 2002-133006, filed on 26 Apr 2002, PENDING
 Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, GRANTED, Pat.
 No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb
 2000, GRANTED, Pat. No. US 6355670 Division of Ser. No. US 1997-803733,
 filed on 21 Feb 1997, GRANTED, Pat. No. US 6107331
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1986
 INCL INCLM: 514/310.000
 INCLS: 514/319.000; 514/343.000; 514/408.000

NCL NCLM: 514/310.000
 NCLS: 514/319.000; 514/343.000; 514/408.000
 IC [7]
 ICM: A61K031-4709
 ICS: A61K031-454; A61K031-4439; A61K031-40
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:93420 USPATFULL
 TI Methods and kits for treating depression or preventing deterioration of cognitive function
 IN Day, Wesley W., San Diego, CA, UNITED STATES
 Lee, Andrew G., Old Lyme, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 Petrie, Charles D., Cranston, RI, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005080099 A1 20050414
 AI US 2004-956896 A1 20040930 (10)
 RLI Division of Ser. No. US 2002-132907, filed on 24 Apr 2002, ABANDONED
 PRAI US 2001-286433P 20010425 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1554
 INCL INCLM: 514/266.200
 INCLS: 514/275.000; 514/314.000; 514/310.000
 NCL NCLM: 514/266.200
 NCLS: 514/275.000; 514/310.000; 514/314.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-505; A61K031-4709
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75833 USPATFULL
 TI 2-alkylidene-19-nor-vitamin D derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005065134 A1 20050324
 AI US 2004-944368 A1 20040916 (10)
 PRAI US 2003-504510P 20030919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1104
 INCL INCLM: 514/167.000
 NCL NCLM: 514/167.000
 IC [7]
 ICM: A61K031-59
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75832 USPATFULL
 TI Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective

agonist
 IN Lee, Andrew G., Old Lyme, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005065133 A1 20050324
 AI US 2004-944119 A1 20040916 (10)
 PRAI US 2003-503798P 20030919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4480
 INCL INCLM: 514/167.000
 INCLS: 514/345.000
 NCL NCLM: 514/167.000
 NCLS: 514/345.000
 IC [7]
 ICM: A61K031-59
 ICS: A61K031-44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75831 USPATFULL
 TI 2-alkylidene-19-nor-vitamin D derivatives for the treatment or prevention of a secon hip fracture
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005065132 A1 20050324
 AI US 2004-944065 A1 20040916 (10)
 PRAI US 2003-504004P 20030919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1121
 INCL INCLM: 514/167.000
 NCL NCLM: 514/167.000
 IC [7]
 ICM: A61K031-59
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75830 USPATFULL
 TI 2-alkylidene-19-nor-vitamin D derivatives for enhancement of peak bone mass in adolescence
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2005065131 A1 20050324
 AI US 2004-944063 A1 20040916 (10)
 PRAI US 2003-504511P 20030919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1112
 INCL INCLM: 514/167.000
 NCL NCLM: 514/167.000
 IC [7]
 ICM: A61K031-59
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75829 USPATFULL
 TI Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxygenase-2 inhibitor
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc. (U.S. corporation)
 PI US 2005065130 A1 20050324
 AI US 2004-943561 A1 20040916 (10)
 PRAI US 2003-504003P 20030919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1536
 INCL INCLM: 514/167.000
 INCLS: 514/406.000; 514/378.000
 NCL NCLM: 514/167.000
 NCLS: 514/378.000; 514/406.000
 IC [7]
 ICM: A61K031-59
 ICS: A61K031-42; A61K031-415
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2005:75787 USPATFULL
 TI Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone
 IN **Thompson, David D.**, Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc. (U.S. corporation)
 PI US 2005065088 A1 20050324
 AI US 2004-946585 A1 20040916 (10)
 PRAI US 2003-504503P 20030919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1427
 INCL INCLM: 514/012.000
 INCLS: 514/167.000
 NCL NCLM: 514/012.000
 NCLS: 514/167.000
 IC [7]
 ICM: A61K038-29
 ICS: A61K031-59
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2004:328061 USPATFULL
 TI Compositions and methods for treating osteoporosis and lowering cholesterol
 IN Day, Wesley W., San Diego, CA, UNITED STATES
 Lee, Andrew G., Old Lyme, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc (U.S. corporation)
 PI US 2004259886 A1 20041223
 AI US 2004-840577 A1 20040506 (10)
 RLI Division of Ser. No. US 2001-767625, filed on 23 Jan 2001, GRANTED, Pat. No. US 6756401

PRAI US 2000-188923P 20000126 (60)
 US 2000-205327P 20000421 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1856
 INCL INCLM: 514/256.000
 INCLS: 514/266.200; 514/266.210; 514/423.000; 514/460.000; 514/548.000
 NCL NCLM: 514/256.000
 NCLS: 514/266.200; 514/266.210; 514/423.000; 514/460.000; 514/548.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-506; A61K031-401
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	2004:228075 USPATFULL	
TI	Prevention of loss and restoration of bone mass by certain prostaglandin agonists	
IN	Cameron, Kimberly O., East Lyme, CT, UNITED STATES Ke, Hua Z., Ledyard, CT, UNITED STATES Lefker, Bruce A., Gales Ferry, CT, UNITED STATES Rosati, Robert L., Mystic, CT, UNITED STATES Thompson, David D. , Gales Ferry, CT, UNITED STATES	
PA	Pfizer Inc (U.S. corporation)	
PI	US 2004176461	A1 20040909
AI	US 2003-652188	A1 20030829 (10)
RLI	Division of Ser. No. <u>US 2002-256985</u> , filed on 26 Sep 2002, GRANTED, Pat. No. <u>US 6649657</u> Division of Ser. No. <u>US 2001-897824</u> , filed on 29 Jun 2001, GRANTED, Pat. No. <u>US 6492412</u> Division of Ser. No. <u>US 1999-331081</u> , filed on 11 Jun 1999, GRANTED, Pat. No. <u>US 6288120</u> A 371 of International Ser. No. <u>WO 1997-IB1417</u> , filed on 10 Nov 1997, UNKNOWN	
<u>PRAI</u>	<u>US 1996-33451P</u>	19961220 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	9724	
INCL	INCLM: 514/602.000 INCLS: 514/478.000; 560/012.000; 564/086.000	
NCL	NCLM: 514/602.000 NCLS: 514/478.000; 560/012.000; 564/086.000	
IC	[7] ICM: A61K031-325 ICS: A61K031-185; A61K031-18	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 11 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	2004:121090 USPATFULL	
TI	Compositions and methods for treating conditions responsive to estrogen	
IN	Thompson, David D. , Gales Ferry, CT, UNITED STATES Lee, Andrew G., Old Tyme, CT, UNITED STATES Day, Wesley W., Old Tyme, CT, UNITED STATES Rosati, Robert L., Stonington, CT, UNITED STATES	
PA	Pfizer Inc (U.S. corporation)	
PI	US 2004092506	A1 20040513
AI	US 2003-652186	A1 20030829 (10)
RLI	Division of Ser. No. <u>US 2001-758778</u> , filed on 11 Jan 2001, GRANTED, Pat. No. <u>US 6632834</u>	

PRAI US 2000-175752P 20000112 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2385
 INCL INCLM: 514/217.060
 INCLS: 514/217.070; 514/228.200; 514/234.200; 514/235.800; 514/266.200;
 514/256.000; 514/307.000; 514/314.000; 514/252.170; 514/252.180
 NCL NCLM: 514/217.060
 NCLS: 514/217.070; 514/228.200; 514/234.200; 514/235.800; 514/252.170;
 514/252.180; 514/256.000; 514/266.200; 514/307.000; 514/314.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-541; A61K031-5377; A61K031-517; A61K031-506; A61K031-4709
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	2004:13471	USPATFULL
TI	Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions	
IN	MacLean, David B., Providence, RI, UNITED STATES Thompson, David D. , Gales Ferry, CT, UNITED STATES	
PA	Pfizer Inc. (U.S. corporation)	
PI	<u>US 2004009994</u>	A1 20040115
AI	<u>US 2003-615282</u>	A1 20030707 (10)
RLI	Division of Ser. No. <u>US 2001-999291</u> , filed on 15 Nov 2001, GRANTED, Pat. No. <u>US 6613796</u> Division of Ser. No. <u>US 2000-511806</u> , filed on 23 Feb 2000, GRANTED, Pat. No. <u>US 6355670</u> Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, GRANTED, Pat. No. <u>US 6107331</u>	
PRAI	<u>US 1996-13212P</u>	19960228 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	2058	
INCL	INCLM: 514/266.200 INCLS: 514/266.220; 514/256.000; 514/307.000; 514/314.000	
NCL	NCLM: 514/266.200 NCLS: 514/256.000; 514/266.220; 514/307.000; 514/314.000	
IC	[7] ICM: A61K031-517 ICS: A61K031-506; A61K031-4709	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 13 OF 78 USPATFULL on STN

	Full Text	Citing References
AN	2003:312744	USPATFULL
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions	
IN	MacLean, David B., Providence, RI, UNITED STATES Thompson, David D. , Gales Ferry, CT, UNITED STATES	
PI	<u>US 2003220349</u>	A1 20031127
	<u>US 6911456</u>	B2 20050628
AI	<u>US 2002-133006</u>	A1 20020426 (10)
RLI	Division of Ser. No. <u>US 2001-803516</u> , filed on 9 Mar 2001, GRANTED, Pat. No. <u>US 6403611</u> Division of Ser. No. <u>US 2000-511806</u> , filed on 23 Feb 2000, GRANTED, Pat. No. <u>US 6355670</u> Division of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, GRANTED, Pat. No. <u>US 6107331</u>	
PRAI	<u>US 1996-13212P</u>	19960228 (60)
DT	Utility	

FS APPLICATION

LN.CNT 2038

INCL INCLM: 514/256.000

INCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000; 514/339.000;
514/394.000; 514/415.000

NCL NCLM: 514/315.000

NCL NCLM: 514/256.000

NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000;
514/314.000; 514/339.000; 514/394.000; 514/415.000

IC [7]

ICM: A61K031-517

ICS: A61K031-506; A61K031-4709; A61K031-4184; A61K031-4439; A61K031-404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 78 USPATFULL on STN

Full
TextCiting
References

AN 2003:238473 USPATFULL

TI Pharmaceutical compositions and methods for administering EP2 receptor
selective agonists

IN Dumont, Francis, Ledyard, CT, UNITED STATES

Hong, Jinyang, Stonington, CT, UNITED STATES

Kim, Yesook, Branford, CT, UNITED STATES

Korsmeyer, Richard W., Old Lyme, CT, UNITED STATES

Li, Mei, Westerly, RI, UNITED STATES

Paralkar, Vishwas M., Madison, CT, UNITED STATES

Thompson, David D., Gales Ferry, CT, UNITED STATESPI US 2003166631 A1 20030904AI US 2002-305649 A1 20021126 (10)PRAI US 2001-335156P 20011130 (60)

DT Utility

FS APPLICATION

LN.CNT 2593

INCL INCLM: 514/211.010

INCLS: 514/478.000; 514/521.000; 514/603.000; 514/227.500; 514/255.030;
514/317.000; 514/237.800; 514/218.000; 514/217.120; 514/365.000;
514/374.000; 514/408.000; 514/400.000

NCL NCLM: 514/211.010

NCLS: 514/217.120; 514/218.000; 514/227.500; 514/237.800; 514/255.030;
514/317.000; 514/365.000; 514/374.000; 514/400.000; 514/408.000;
514/478.000; 514/521.000; 514/603.000

IC [7]

ICM: A61K031-55

ICS: A61K031-553; A61K031-554; A61K031-54; A61K031-537; A61K031-496;

A61K031-426; A61K031-421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 78 USPATFULL on STN

Full
TextCiting
References

AN 2003:232606 USPATFULL

TI Compositions and methods for treating osteoporosis and lowering
cholesterol

IN Day, Wesley W., Old Lyme, CT, UNITED STATES

Lee, Andrew G., Old Lyme, CT, UNITED STATES

Thompson, David D., Gales Ferry, CT, UNITED STATESPI US 2003162807 A1 20030828US 6756401 B2 20040629AI US 2001-767625 A1 20010123 (9)PRAI US 2000-188293P 20000308 (60)

US 2000-205327P 20000421 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1958
 INCL INCLM: 514/307.000
 INCLS: 514/319.000; 514/412.000; 514/408.000
 NCL NCLM: 514/428.000
 NCL NCLM: 514/307.000
 NCLS: 514/461.000; 514/473.000; 514/319.000; 514/408.000; 514/412.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-445
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2003:181486 USPATFULL
TI	Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
IN	Day, Wesley W., San Diego, CA, UNITED STATES Lee, Andrew G., Old Lyme, CT, UNITED STATES Thompson, David D., Gales Ferry, CT, UNITED STATES
PI	US 2003125319 A1 20030703
AI	US 2002-292203 A1 20021112 (10)
RLI	Division of Ser. No. US 2001-976825, filed on 12 Oct 2001, PENDING
PRAI	US 2000-240789P 20001016 (60)
DT	Utility
FS	APPLICATION
LN.CNT	4739
INCL	INCLM: 514/217.060 INCLS: 514/217.070; 514/256.000; 514/266.200; 514/266.220; 514/228.200; 514/232.800; 514/252.170; 514/252.180; 514/314.000; 514/319.000; 514/318.000
NCL	NCLM: 514/217.060 NCLS: 514/217.070; 514/228.200; 514/232.800; 514/252.170; 514/252.180; 514/256.000; 514/266.200; 514/266.220; 514/314.000; 514/318.000; 514/319.000
IC	[7] ICM: A61K031-55 ICS: A61K031-541; A61K031-5377; A61K031-517; A61K031-506; A61K031-496; A61K031-4709; A61K031-4545 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2003:166582 USPATFULL
TI	Compositions and methods of treatment for conditions responsive to testosterone elevation
IN	Lee, Andrew G., Old Lyme, CT, UNITED STATES Day, Wesley W., Old Lyme, CT, UNITED STATES Thompson, David D., Gales Ferry, CT, UNITED STATES
PI	US 2003114440 A1 20030619
AI	US 2002-301930 A1 20021121 (10)
RLI	Division of Ser. No. US 2001-757423, filed on 10 Jan 2001, GRANTED, Pat. No. US 6512002
PRAI	US 2000-175704P 20000112 (60)
DT	Utility
FS	APPLICATION

LN.CNT 2198

INCL INCLM: 514/217.060

INCLS: 514/217.070; 514/256.000; 514/266.200; 514/266.220; 514/252.170;
514/252.180; 514/314.000; 514/318.000; 514/319.000; 514/649.000;
514/228.200; 514/232.800; 514/233.800

NCL NCLM: 514/217.060

NCLS: 514/217.070; 514/228.200; 514/232.800; 514/233.800; 514/252.170;
514/252.180; 514/256.000; 514/266.200; 514/266.220; 514/314.000;
514/318.000; 514/319.000; 514/649.000

IC [7]

ICM: A61K031-55

ICS: A61K031-541; A61K031-5377; A61K031-517; A61K031-496; A61K031-506;
A61K031-4709; A61K031-137; A61K031-4545

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 18 OF 78 USPATFULL on STN

Full
TextCiting
References

AN 2003:153424 USPATFULL

TI Prevention of loss and restoration of bone mass by certain prostaglandin
agonists

IN Cameron, Kimberley Q., East Lyme, CT, UNITED STATES

Ke, Hua Z., Ledyard, CT, UNITED STATES

Lefker, Bruce A., Gales Ferry, CT, UNITED STATES

Rosati, Robert L., Mystic, CT, UNITED STATES

Thompson, David D., Gales Ferry, CT, UNITED STATESPI US 2003105092 A1 20030605US 6649657 B2 20031118AI US 2002-256985 A1 20020926 (10)RLI Division of Ser. No. US 2001-897824, filed on 29 Jun 2001, GRANTED, Pat.
No. US 6492412

DT Utility

FS APPLICATION

LN.CNT 9746

INCL INCLM: 514/227.500

INCLS: 514/238.200; 514/252.100; 514/357.000; 514/365.000; 514/385.000;
514/399.000; 514/406.000; 514/602.000; 544/059.000; 544/159.000;
544/402.000; 546/334.000; 548/193.000; 548/235.000; 548/335.500;
564/095.000

NCL NCLM: 514/545.000

NCL NCLM: 514/227.500

NCLS: 514/438.000; 514/461.000; 514/570.000; 549/070.000; 549/484.000;
560/051.000; 562/459.000; 514/238.200; 514/252.100; 514/357.000;
514/365.000; 514/385.000; 514/399.000; 514/406.000; 514/602.000;
544/059.000; 544/159.000; 544/402.000; 546/334.000; 548/193.000;
548/235.000; 548/335.500; 564/095.000

IC [7]

ICM: A61K031-54

ICS: A61K031-537; A61K031-495; A61K031-44; A61K031-426; A61K031-421;
A61K031-4172; A61K031-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 78 USPATFULL on STN

Full
TextCiting
References

AN 2003:134630 USPATFULL

TI Methods and kits for treating depression or preventing deterioration of
cognitive function

IN Day, Wesley W., San Diego, CA, UNITED STATES

Lee, Andrew G., Old Lyme, CT, UNITED STATES

Thompson, David D., Gales Ferry, CT, UNITED STATES

Petrie, Charles D., Cranston, RI, UNITED STATES

PI US 2003092719 A1 20030515
 AI US 2002-132907 A1 20020424 (10)
 PRAI US 2001-286433P 20010425 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1868
 INCL INCLM: 514/256.000
 INCLS: 514/266.200; 514/266.100; 514/266.210; 514/314.000; 514/307.000;
 514/337.000; 514/732.000
 NCL NCLM: 514/256.000
 NCLS: 514/266.100; 514/266.200; 514/266.210; 514/307.000; 514/314.000;
 514/337.000; 514/732.000
 IC [7]
 ICM: A61K031-505
 ICS: A61K031-517; A61K031-47; A61K031-4709; A61K031-4439; A61K031-05
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2003:93656 USPATFULL
 TI Pharmaceutical compositions, kits and methods comprising combinations of
 estrogen agonists / antagonists, estrogens and progestins
 IN HuaZhu, Ke, Ledyard, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PI US 2003065017 A1 20030403
 AI US 2002-206587 A1 20020726 (10)
 PRAI US 2001-309065P 20010731 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1342
 INCL INCLM: 514/408.000
 NCL NCLM: 514/408.000
 IC [7]
 ICM: A61K031-40
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:280644 USPATFULL
 TI Methods and kits for improving vascular health
 IN Day, Wesley W., San Diego, CA, UNITED STATES
 Lee, Andrew G., Old Lyme, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PI US 2002156090 A1 20021024
 US 6620806 B2 20030916
 AI US 2001-977458 A1 20011015 (9)
 PRAI US 2000-241532P 20001017 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2950
 INCL INCLM: 514/266.200
 INCLS: 514/266.210; 514/256.000; 514/314.000; 514/307.000; 514/337.000;
 514/394.000; 514/415.000
 NCL NCLM: 514/217.030
 NCL NCLM: 514/266.200
 NCLS: 514/211.150; 514/217.080; 514/218.000; 514/307.000; 514/315.000;

514/317.000; 514/323.000; 514/331.000; 514/345.000; 514/414.000;
 514/415.000; 514/428.000; 514/582.000; 514/585.000; 514/648.000;
 514/256.000; 514/266.210; 514/314.000; 514/337.000; 514/394.000

IC [7]

ICM: A61K031-517

ICS: A61K031-506; A61K031-4709; A61K031-47; A61K031-404; A61K031-4439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:236078 USPATFULL

TI Methods for assessing, improving, or maintaining urogenital health in postmenopausal women

IN Day, Wesley W., San Diego, CA, UNITED STATES

Lee, Andrew W., Old Lyme, CT, UNITED STATES

Thompson, David D., Gales Ferry, CT, UNITED STATES

PI US 2002128276 A1 20020912

AI US 2001-976825 A1 20011012 (9)

PRAI US 2000-240789P 20001016 (60)

DT Utility

FS APPLICATION

LN.CNT 4685

INCL INCLM: 514/256.000

INCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000

NCL NCLM: 514/256.000

NCLS: 514/266.200; 514/266.210; 514/307.000; 514/314.000

IC [7]

ICM: A61K031-517

ICS: A61K031-506; A61K031-4709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:209558 USPATFULL

TI Dosing regimens for lasofoxifene

IN **Thompson, David D.**, Gales Ferry, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6436977 B1 20020820

AI US 2000-656273 20000906 (9)

PRAI US 1999-156652P 19990929 (60)

DT Utility

FS GRANTED

LN.CNT 254

INCL INCLM: 514/367.000

INCLS: 514/377.000

NCL NCLM: 514/367.000

NCLS: 514/377.000

IC [7]

ICM: A61K031-425

ICS: A61K031-42

EXF 514/367; 514/377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 24 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:188358 USPATFULL

TI Prevention and treatment of skeletal disorder with EP2 receptor subtype

selective prostaglandin E2 agonists

IN Cameron, Kimberly O., East Lyme, CT, United States
 Ke, Hua Z., Ledyard, CT, United States
 Lefker, Bruce A., Gales Ferry, CT, United States
 Rosati, Robert L, Mystic, CT, United States
Thompson, David D., Gales Ferry, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6426359 B1 20020730
WO 9827976 19980702

AI US 1999-331078 19990611 (9)
WO 1997-IB1483 19971127
 19990611 PCT 371 date

PRAI US 1996-33569P 19961220 (60)

DT Utility

FS GRANTED

LN.CNT 2773

INCL INCLM: 514/381.000
 INCLS: 514/488.000; 514/601.000; 435/366.000; 548/252.000; 548/254.000;
 549/071.000; 568/030.000

NCL NCLM: 514/381.000
 NCLS: 435/366.000; 514/488.000; 514/601.000; 548/252.000; 548/254.000;
 549/071.000; 568/030.000

IC [7]
 ICM: A61K031-41
 ICS: C07C317-00; C07D257-04

EXF 514/381; 514/488; 514/601; 548/252; 548/254; 549/71; 568/30; 435/366

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 25 OF 78 USPATFULL on STN

Full
Text

Ching
References

AN 2002:172363 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting
 pathological conditions

IN MacLean, David B., Providence, RI, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES

PI US 2002091121 A1 20020711
US 6613796 B2 20030902

AI US 2001-999291 A1 20011115 (9)

RLI Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, PATENTED
 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, PATENTED

PRAI US 1996-13212P 19960228 (60)

DT Utility

FS APPLICATION

LN.CNT 2060

INCL INCLM: 514/217.010
 INCLS: 514/221.000; 514/256.000; 514/266.200; 514/266.210; 514/307.000;
 514/314.000

NCL NCLM: 514/428.000

NCL NCLM: 514/217.010
 NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000;
 514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000

IC [7]
 ICM: A61K031-55
 ICS: A61K031-5513; A61K031-517; A61K031-506; A61K031-4709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 78 USPATFULL on STN

Full
Text

Ching
References

AN 2002:73008 USPATFULL
 TI EP4 receptor selective agonists in the treatment of osteoporosis
 IN Cameron, Kimberly O., East Lyme, CT, UNITED STATES
 Ke, HuaZhu, Ledyard, CT, UNITED STATES
 Lefker, Bruce A., Gales Ferry, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PI US 2002040149 A1 20020404
US 6642266 B2 20031104
 AI US 2001-991585 A1 20011116 (9)
 RLI Division of Ser. No. US 2000-738670, filed on 15 Dec 2000, PENDING
 PRAI US 1999-171353P 19991222 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1849
 INCL INCLM: 548/253.000
 INCLS: 514/381.000; 514/424.000; 548/550.000; 548/551.000
 NCL NCLM: 514/424.000
 NCL NCLM: 548/253.000
 NCLS: 514/381.000; 548/551.000; 548/550.000
 IC [7]
 ICM: A61K031-41
 ICS: A61K031-4015; C07D043-02; C07D027-27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:51000 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
 IN Maclean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer, Inc., New York, NY, United States (U.S. corporation)
 PI US 6355670 B1 20020312
 AI US 2000-511806 20000223 (9)
 RLI Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997
 PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2011
 INCL INCLM: 514/428.000
 INCLS: 514/343.000; 514/319.000
 NCL NCLM: 514/428.000
 NCLS: 514/319.000; 514/343.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-44; A61K031-445
 EXF 514/319; 514/428; 514/343
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:27520 USPATFULL
 TI Prevention of loss and restoration of bone mass by certain prostaglandin agonists
 IN Cameron, Kimberly O., East Lyme, CT, UNITED STATES
 Ke, Hua Z., Ledyard, CT, UNITED STATES
 Lefker, Bruce A., Gales Ferry, CT, UNITED STATES
 Rosati, Robert L., Mystic, CT, UNITED STATES

Thompson, David D., Gales Ferry, CT, UNITED STATES

PI US 2002016368 A1 20020207
 US 6492412 B2 20021210
 AI US 2001-897824 A1 20010629 (9)
 RLI Division of Ser. No. US 1999-331081, filed on 11 Jun 1999, GRANTED, Pat.
 No. US 6288120 A 371 of International Ser. No. WO 1997-IB1417, filed on
 10 Nov 1997, UNKNOWN
 PRAI US 1996-33451P 19961220 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9918
 INCL INCLM: 514/601.000
 INCLS: 514/575.000; 514/626.000; 514/665.000; 562/623.000; 564/095.000;
 564/193.000; 564/440.000
 NCL NCLM: 514/423.000
 NCL NCLM: 514/601.000
 NCLS: 514/252.100; 514/255.050; 514/256.000; 514/448.000; 514/570.000;
 514/605.000; 544/335.000; 544/336.000; 548/531.000; 549/072.000;
 562/470.000; 564/099.000; 514/575.000; 514/626.000; 514/665.000;
 562/623.000; 564/095.000; 564/193.000; 564/440.000
 IC [7]
 ICM: A61K031-185
 ICS: A61K031-18; A61K031-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 29 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2002:22491 USPATFULL
 TI Compositions and methods for treating female sexual dysfunction
 IN Lee, Andrew G., Old Lyme, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 Day, Wesley W., Old Lyme, CT, UNITED STATES
 PI US 2002013327 A1 20020131
 AI US 2001-833169 A1 20010411 (9)
 PRAI US 2000-266387P 20000418 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2652
 INCL INCLM: 514/256.000
 INCLS: 514/259.000; 514/307.000; 514/314.000; 514/338.000; 514/339.000
 NCL NCLM: 514/256.000
 NCLS: 514/307.000; 514/314.000; 514/338.000; 514/339.000; 544/262.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-506; A61K031-4725; A61K031-4709; A61K031-4439
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 30 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:237979 USPATFULL
 TI Method of reducing morbidity and the risk of mortality
 IN Day, Wesley W., Old Lyme, CT, United States
 Lee, Andrew G., Old Lyme, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PI US 2001056099 A1 20011227
 AI US 2001-757817 A1 20010110 (9)
 PRAI US 2000-175663P 20000112 (60)
 DT Utility

FS APPLICATION
 LN.CNT 1997
 INCL INCLM: 514/307.000
 INCLS: 514/319.000; 514/320.000; 514/408.000; 514/412.000
 NCL NCLM: 514/307.000
 NCLS: 514/319.000; 514/320.000; 514/408.000; 514/412.000
 IC [7]
 ICM: A61K031-453
 ICS: A61K031-445; A61K031-40
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 31 OF 78 USPATFULL on STN

Full Text	Citing References
AN 2001:237940	USPATFULL
TI Treatment of osteoporosis with EP2/EP4 receptor selective agonists	
IN Cameron, Kimberly O., East Lyme, CT, United States	
Ke, HuaZhu, Ledyard, CT, United States	
Lefker, Bruce A., Gales Ferry, CT, United States	
Thompson, David D. , Gales Ferry, CT, United States	
PI <u>US 2001056060</u>	A1 20011227
AI <u>US 2001-776430</u>	A1 20010202 (9)
PRAI <u>US 2000-180635P</u>	20000207 (60)
DT Utility	
FS APPLICATION	
LN.CNT 1737	
INCL INCLM: 514/001.000	
NCL NCLM: 514/001.000	
IC [7]	
ICM: A61K031-00	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 32 OF 78 USPATFULL on STN

Full Text	Citing References
AN 2001:218612	USPATFULL
TI EP4 receptor selective agonists in the treatment of osteoporosis	
IN Cameron, Kimberly O., East Lyme, CT, United States	
Ke, HuaZhu, Ledyard, CT, United States	
Lefker, Bruce A., Gales Ferry, CT, United States	
Thompson, David D. , Gales Ferry, CT, United States	
PI <u>US 2001047105</u>	A1 20011129
<u>US 6737437</u>	B2 20040518
AI <u>US 2000-738670</u>	A1 20001215 (9)
PRAI <u>US 1999-171353P</u>	19991222 (60)
DT Utility	
FS APPLICATION	
LN.CNT 1820	
INCL INCLM: 560/001.000	
INCLS: 514/381.000; 514/454.000; 548/253.000; 548/551.000	
NCL NCLM: 514/424.000	
NCL NCLM: 560/001.000	
NCLS: 548/253.000; 548/551.000	
IC [7]	
ICM: C07D257-00	
ICS: A61K031-41; A01N043-64; A61K031-35; A01N043-16; C07D207-12;	
C07D207-24; C07D207-36	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 33 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:215078 USPATFULL
 TI Combination therapy for osteoporosis
 IN Ke, Hua Zhu, Ledyard, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6323232 B1 20011127
WO 9731640 19970904
 AI US 1998-117972 19980811 (9)
WO 1996-IB1462 19961223
 19980811 PCT 371 date
 19980811 PCT 102(e) date
 PRAI US 1996-12412P 19960228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2001
 INCL INCLM: 514/408.000
 INCLS: 514/648.000; 514/443.000
 NCL NCLM: 514/408.000
 NCLS: 514/443.000; 514/648.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-13; A61K031-38
 EXF 514/648; 514/443; 514/337; 514/257; 514/408
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 34 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:212438 USPATFULL
 TI Compositions and methods of treatment for conditions responsive to testosterone elevation
 IN Lee, Andrew G., Old Lyme, CT, United States
 Day, Wesley W., Old Lyme, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PI US 2001044434 A1 20011122
US 6512002 B2 20030128
 AI US 2001-757423 A1 20010110 (9)
 PRAI US 2000-175704P 20000112 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2192
 INCL INCLM: 514/217.030
 INCLS: 514/317.000; 514/217.080; 514/415.000; 514/648.000
 NCL NCLM: 514/427.000
 NCL NCLM: 514/217.030
 NCLS: 514/410.000; 514/415.000; 514/428.000; 514/429.000; 514/217.080;
 514/317.000; 514/648.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-454; A61K031-404; A61K031-135
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 35 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:205936 USPATFULL
 TI Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure

IN Paralkar, Vishwas M., Madison, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PI US 2001041729 A1 20011115
US 6610719 B2 20030826
 AI US 2001-771164 A1 20010129 (9)
 PRAI US 2000-178968P 20000131 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 671
 INCL INCLM: 514/381.000
 INCLS: 514/424.000
 NCL NCLM: 514/381.000
 NCL NCLM: 514/381.000
 NCLS: 514/352.000; 514/423.000; 514/530.000; 514/573.000; 514/424.000
 IC [7]
 ICM: A61K031-41
 ICS: A01N043-64; A61K031-40; A01N043-36
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 36 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2001:205925 USPATFULL
TI	Compositions and methods for treating conditions responsive to estrogen
IN	Thompson, David D. , Gales Ferry, CT, United States Lee, Andrew G., Old Lyme, CT, United States Day, Wesely W., Old Lyme, CT, United States Rosati, Robert L., Stonington, CT, United States
PI	<u>US 2001041718</u> A1 20011115 <u>US 6632834</u> B2 20031014
AI	<u>US 2001-758778</u> A1 20010111 (9)
PRAI	<u>US 2000-175752P</u> 20000112 (60)
DT	Utility
FS	APPLICATION
LN.CNT	2385
INCL	INCLM: 514/317.000 INCLS: 514/308.000; 514/408.000
NCL	NCLM: 514/428.000
NCL	NCLM: 514/317.000 NCLS: 514/308.000; 514/408.000
IC	[7] ICM: A61K031-4725 ICS: A61K031-445; A61K031-40 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 37 OF 78 USPATFULL on STN

Full Text	Citing References
AN	2001:194421 USPATFULL
TI	Compositions and methods for treating osteoporosis
IN	Day, Wesley W., Old Lyme, CT, United States Thompson, David D. , Gales Ferry, CT, United States Lee, Andrew G., Old Lyme, CT, United States
PI	<u>US 2001036936</u> A1 20011101
AI	<u>US 2001-782433</u> A1 20010213 (9)
PRAI	<u>US 2000-182713P</u> 20000215 (60)
DT	Utility
FS	APPLICATION
LN.CNT	1114
INCL	INCLM: 514/102.000

INCLS: 514/091.000; 514/423.000; 514/460.000
 NCL NCLM: 514/102.000
 NCLS: 514/091.000; 514/423.000; 514/460.000
 IC [7]
 ICM: A61K031-675
 ICS: A61K031-662; A61K031-366; A61K031-40
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 38 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:153016 USPATFULL
 TI Prevention of loss and restoration of bone mass by certain prostaglandin agonists
 IN Cameron, Kimberly O., East Lyme, CT, United States
 Ke, Hua Z., Ledyard, CT, United States
 Lefker, Bruce A., Gales Ferry, CT, United States
 Rosati, Robert L., Mystic, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6288120 B1 20010911
 WO 9828264 19980702
 AI US 1999-331081 19990611 (9)
 WO 1997-IB1417 19971110
 19990611 PCT 371 date
 19990611 PCT 102(e) date
 PRAI US 1996-33451P 19961220 (60)
 DT Utility
 FS GRANTED
 LN.CNT 9116
 INCL INCLM: 514/605.000
 INCLS: 514/570.000; 564/099.000; 562/470.000
 NCL NCLM: 514/605.000
 NCLS: 514/570.000; 562/470.000; 564/099.000
 IC [7]
 ICM: A61K031-16
 ICS: A61K031-19; C07C303-00; C07C059-48
 EXF 562/470; 514/570; 514/605; 564/99
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 39 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:147980 USPATFULL
 TI Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
 IN Ke, HuaZhu, Ledyard, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6284773 B1 20010904
 AI US 1999-314371 19990714 (9)
 PRAI US 1998-89468P 19980616 (60)
 DT Utility
 FS GRANTED
 LN.CNT 643
 INCL INCLM: 514/317.000
 INCLS: 514/573.000
 NCL NCLM: 514/317.000
 NCLS: 514/573.000
 IC [7]

ICM: A61K031-445

ICS: A61K031-19; A61K031-557

EXF 514/317; 514/573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 40 OF 78 USPATFULL on STN

Full Text	References
-----------	------------

AN 2001:145314 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN Maclean, David B., Providence, RI, United States

Thompson, David D., Gales Ferry, CT, United StatesPI US 2001018451 A1 20010830US 6403611 B2 20020611AI US 2001-803516 A1 20010309 (9)RLI Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, PENDING
Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED,
Pat. No. US 6107331PRAI US 1996-13212P 19960228 (60)

DT Utility

FS APPLICATION

LN.CNT 2063

INCL INCLM: 514/428.000

INCLS: 514/320.000; 514/304.000

NCL NCLM: 514/315.000

NCL NCLM: 514/428.000

NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000

IC [7]

ICM: A61K031-445

ICS: A61K031-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 41 OF 78 USPATFULL on STN

Full Text	References
-----------	------------

AN 2001:131333 USPATFULL

TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

IN MacLean, David B., Providence, RI, United States

Thompson, David D., Gales Ferry, CT, United States

PA Pfizer Inc, New York, NY, United States (U.S. corporation)

PI US 6274618 B1 20010814AI US 1999-314758 19990519 (9)RLI Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, now patented, Pat. No. US 6107331PRAI US 1996-13212P 19960228 (60)

DT Utility

FS GRANTED

LN.CNT 1933

INCL INCLM: 514/428.000

INCLS: 514/213.000; 514/317.000; 514/331.000

NCL NCLM: 514/428.000

NCLS: 514/317.000; 514/331.000

IC [7]

ICM: A61K031-40

ICS: A01N043-36

EXF 514/317; 514/213; 514/331; 514/428

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 42 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2001:119297 USPATFULL
 TI Combination therapy for osteoporosis
 IN Ke, Hua Zhu, Ledyard, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PI US 2001009920 A1 20010726
 AI US 2000-736051 A1 20001213 (9)
 RLI Division of Ser. No. US 1998-117972, filed on 11 Aug 1998, PENDING A 371
 of International Ser. No. WO 1996-IB1462, filed on 23 Dec 1996, UNKNOWN
 PRAI US 1996-12412P 19960228 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2509
 INCL INCLM: 514/408.000
 INCLS: 514/559.000
 NCL NCLM: 514/408.000
 NCLS: 514/559.000
 IC [7]
 ICM: A61K031-20
 ICS: A01N037-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 43 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:137864 USPATFULL
 TI Therapeutic combinations comprising a selective estrogen receptor
 modulator and parathyroid hormone
 IN Ke, HuaZhu, Ledyard, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6132774 20001017
WO 9965482 19991223
 AI US 1999-424010 19991115 (9)
WO 1999-IB949 19990526
 19991115 PCT 371 date
 19991115 PCT 102(e) date
 PRAI US 1998-89479P 19980616 (60)
 DT Utility
 FS Granted
 LN.CNT 650
 INCL INCLM: 424/520.000
 INCLS: 514/428.000
 NCL NCLM: 424/520.000
 NCLS: 514/428.000
 IC [7]
 ICM: A61K035-12
 ICS: A61K031-40
 EXF 514/428; 424/520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 44 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 2000:109836 USPATFULL
 TI Use of estrogen antagonists and estrogen agonists in inhibiting
 pathological conditions
 IN MacLean, David B., Providence, RI, United States

Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6107331 20000822
AI US 1997-803733 19970221 (8)
PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 1927
 INCL INCLM: 514/428.000
 INCLS: 514/427.000
 NCL NCLM: 514/428.000
 NCLS: 514/427.000
 IC [7]
 ICM: A61K031-40
 EXF 514/427; 514/428
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 45 OF 78 USPATFULL on STN

Full Text	References
AN	2000:102333 USPATFULL

TI Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
 IN Maclean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6100301 20000808
AI US 1998-92100 19980605 (9)
PRAI US 1996-12409P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 743
 INCL INCLM: 514/648.000
 INCLS: 514/012.000
 NCL NCLM: 514/648.000
 NCLS: 514/012.000
 IC [7]
 ICM: A61K031-135
 ICS: A61K038-00
 EXF 514/648; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 46 OF 78 USPATFULL on STN

Full Text	References
AN	2000:54092 USPATFULL

TI Combination therapy to prevent bone loss-progesterone and estrogen agonists
 IN MacLean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6057309 20000502
AI US 1998-193265 19981116 (9)
RLI Continuation of Ser. No. US 1997-803710, filed on 21 Feb 1997, now abandoned
PRAI US 1996-12400P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 438
 INCL INCLM: 514/171.000

INCLS: 514/648.000
 NCL NCLM: 514/171.000
 NCLS: 514/648.000
 IC [7]
 ICM: A61K031-56
 ICS: A61K031-135
 EXF 514/648; 514/171
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 47 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 2000:9953 USPATFULL
 TI Method of increasing testosterone
 IN MacLean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6017964 20000125
 AI US 1998-208729 19981209 (9)
 RLI Continuation of Ser. No. US 1997-803711, filed on 21 Feb 1997, now abandoned
 PRAI US 1996-21181P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 348
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 48 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 1999:146631 USPATFULL
 TI Inhibition of autoimmune diseases
 IN MacLean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 5985932 19991116
 AI US 1997-804346 19970221 (8)
 PRAI US 1996-12402P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 392
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 49 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 1999:90360 USPATFULL
 TI Method and system for applying dispersive normal moveout corrections to seismic survey signals
 IN Byun, Bok S., Plano, TX, United States

Thompson, David D., Plano, TX, United States
 Nelan, E. Stuart, Dallas, TX, United States
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)
PI US 5933789 19990803
AI US 1996-745452 19961112 (8)
 DT Utility
 FS Granted
 LN.CNT 998
 INCL INCLM: 702/017.000
 INCLS: 367/048.000; 367/052.000; 702/013.000
 NCL NCLM: 702/017.000
 NCLS: 367/048.000; 367/052.000; 702/013.000
 IC [6]
 ICM: G06F019-00
 EXF 702/14; 702/17; 702/13; 367/48; 367/52

L2 ANSWER 50 OF 78 USPATFULL on STN

Full Text	Citing References
AN	1999:56502 USPATFULL
TI	Use of droloxifene for the treatment of cardiovascular disease
IN	Loser, Roland, Feldafing, Germany, Federal Republic of Schliack, Michael, Munich, Germany, Federal Republic of Thompson, David D. , Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
<u>PI</u>	US 5902830 19990511
<u>AI</u>	US 1998-48568 19980326 (9)
<u>RLI</u>	Division of Ser. No. <u>US 1996-605131</u> , filed on 13 Mar 1996
DT	Utility
FS	Granted
LN.CNT	221
INCL	INCLM: 514/648.000
NCL	NCLM: 514/648.000
IC	[6] ICM: A61K031-135
EXF	514/648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 51 OF 78 USPATFULL on STN

Full Text	Citing References
AN	1999:40459 USPATFULL
TI	Method of treating diseases and conditions with estrogen agonists and antagonists
IN	MacLean, David B., Providence, RI, United States Thompson, David D. , Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
<u>PI</u>	US 5889042 19990330
<u>AI</u>	US 1997-803706 19970221 (8)
<u>PRAI</u>	US 1996-13213P 19960228 (60)
DT	Utility
FS	Granted
LN.CNT	1668
INCL	INCLM: 514/127.000
NCL	NCLM: 514/427.000
IC	[6] ICM: A61K031-40
EXF	514/427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 52 OF 78 USPATFULL on STN

Full Text	Class References
-----------	------------------

AN 1999:7425 USPATFULL
 TI Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists
 IN MacLean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5861438 19990119
 AI US 1997-803712 19970221 (8)
 PRAI US 1996-12399P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 530
 INCL INCLM: 514/648.000
 INCLS: 514/012.000
 NCL NCLM: 514/648.000
 NCLS: 514/012.000
 IC [6]
 ICM: A61K038-00
 ICS: A61K031-135
 EXF 514/12; 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 53 OF 78 USPATFULL on STN

Full Text	Class References
-----------	------------------

AN 1998:159989 USPATFULL
 TI Use of droloxifene for the treatment of protastic disease, endometriosis and obesity
 IN **Thompson, David D.**, Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5852059 19981222
WO 9602243 19960201
 AI US 1997-750860 19970106 (8)
WO 1995-IB404 19950526
 19970106 PCT 371 date
 19970106 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1994-276969, filed on 19 Jul 1994, now patented, Pat. No. US 5441986
 DT Utility
 FS Granted
 LN.CNT 220
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 54 OF 78 USPATFULL on STN

Full Text	Class References
-----------	------------------

AN 1998:131754 USPATFULL
 TI Use of droloxifene for the treatment of cardiovascular diseases
 IN Loser, Roland, Feldafing, Germany, Federal Republic of
 Schliack, Michael, Munchen, Germany, Federal Republic of
Thompson, David D., Gales Ferry, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5827892 19981027
 WO 9602242 19960201
 AI US 1996-605131 19960313 (8)
 WO 1995-IB403 19950526
 19960313 PCT 371 date
 19960313 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1994-276969, filed on 19 Jul 1994,
 now patented, Pat. No. US 5441986
 DT Utility
 FS Granted
 LN.CNT 224
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/651; 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 55 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 1998:75623 USPATFULL
 TI Combination therapy to treat osteoporosis - polyphosphonates and
 estrogen agonists
 IN MacLean, David B., Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5773477 19980630
 AI US 1997-803707 19970221 (8)
 PRAI US 1996-12409P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 499
 INCL INCLM: 514/648.000
 INCLS: 514/102.000; 514/108.000
 NCL NCLM: 514/648.000
 NCLS: 514/102.000; 514/108.000
 IC [6]
 ICM: A61K031-135
 ICS: A61K031-66
 EXF 514/648; 514/102; 514/108
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 56 OF 78 USPATFULL on STN

Full Text	Citing References
--------------	----------------------

AN 1998:66277 USPATFULL
 TI Method and system for surface-consistent phase and time lag correction
 of seismic data
 IN **Thompson, David D.**, Plano, TX, United States
 Byun, Bok S., Plano, TX, United States
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S.
 corporation)
 PI US 5764516 19980609
 AI US 1995-580819 19951229 (8)
 DT Utility
 FS Granted
 LN.CNT 1603
 INCL INCLM: 364/421.000

INCLS: 367/054.000
 NCL NCLM: 702/017.000
 NCLS: 367/054.000
 IC [6]
 ICM: G06F019-00
 EXF 364/421; 364/422; 367/48; 367/45; 367/50; 367/54; 367/38; 367/43;
 367/47; 367/49; 367/72; 367/51

L2 ANSWER 57 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:33959 USPATFULL
 TI Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
 IN MacLean, David B., Providence County, RI, United States
 Thompson, David D., New London County, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5733937 19980331
 AI US 1997-804702 19970221 (8)
 PRAI US 1996-12410P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 363
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 58 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:25261 USPATFULL
 TI Protection of ischemic myocardium against reperfusion damage
 IN MacLean, David B., Groton, CT, United States
 Thompson, David D., Groton, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5726207 19980310
 AI US 1997-805040 19970221 (8)
 PRAI US 1996-12401P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 303
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/646
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 59 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:17354 USPATFULL
 TI 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
 IN Maclean, David B., Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5719191 19980217

AI US 1997-805039 19970221 (8)
PRAI US 1996-25201P 19960228 (60)
 DT Utility
 FS Granted
 LN.CNT 424
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 60 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 1998:17353 USPATFULL
 TI Inhibition of myeloperoxidase activity
 IN MacLean, David B., Providence, RI, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5719190 19980217
AI US 1997-803709 19970221 (8)
PRAI US 1986-12403P 19860228 (60)
 DT Utility
 FS Granted
 LN.CNT 362
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: A61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 61 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 96:120892 USPATFULL
 TI Benzothiophene estrogen agonists to treat prostatic hyperplasia
 IN Thompson, David D., Groton, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5589482 19961231
AI US 1994-356011 19941214 (8)
 DT Utility
 FS Granted
 LN.CNT 533
 INCL INCLM: 514/305.000
 INCLS: 324/212.000; 324/210.000; 324/422.000; 324/448.000
 NCL NCLM: 514/305.000
 NCLS: 324/210.000; 324/212.000; 324/422.000; 324/448.000
 IC [6]
 ICM: A61K031-44
 ICS: A61K031-445; A61K031-395; A61K031-40
 EXF 514/443; 514/324; 514/422; 514/578; 514/210; 514/448; 514/470; 514/418;
 514/305; 514/212
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 62 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 95:73667 USPATFULL

TI Estrogen agonists as remedies for prostate and cardiovascular diseases
 IN **Thompson, David D.**, Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5441986 19950815
 AI US 1994-276969 19940719 (8)
 DT Utility
 FS Granted
 LN.CNT 166
 INCL INCLM: 514/648.000
 NCL NCLM: 514/648.000
 IC [6]
 ICM: H61K031-135
 EXF 514/648
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 63 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 92:84017 USPATFULL
 TI Mass retrieval for acoustic pulse generator
 IN **Thompson, David D.**, Plano, TX, United States
 Airhart, Tom P., Plano, TX, United States
 Woodrow, Andrew B., Plano, TX, United States
 Karner, Gary M., Garland, TX, United States
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)
 PI US 5154254 19921013
 AI US 1990-510352 19900416 (7)
 DT Utility
 FS Granted
 LN.CNT 457
 INCL INCLM: 181/121.000
 INCLS: 181/114.000; 367/189.000
 NCL NCLM: 181/121.000
 NCLS: 181/114.000; 367/189.000
 IC [5]
 ICM: G01V001-04
 EXF 367/189; 367/190; 181/113; 181/114; 181/119; 181/121; 181/401

L2 ANSWER 64 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 92:2056 USPATFULL
 TI 3-dimensional migration of irregular grids of 2-dimensional seismic data
 IN Mosher, Charles C., Plano, TX, United States
Thompson, David D., Plano, TX, United States
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)
 PI US 5079703 19920107
 AI US 1990-481868 19900220 (7)
 DT Utility
 FS Granted
 LN.CNT 451
 INCL INCLM: 364/421.000
 INCLS: 364/422.000; 367/051.000; 367/053.000; 367/072.000; 395/127.000
 NCL NCLM: 702/016.000
 NCLS: 345/427.000; 367/051.000; 367/053.000; 367/072.000
 IC [5]
 ICM: G01V001-00
 ICS: G06F015-00

EXF 367/53; 367/51; 367/72; 364/421; 364/521; 364/522

L2 ANSWER 65 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 91:78304 USPATFULL
 TI Method and apparatus for seismic survey including using vertical gradient estimation to separate downgoing seismic wavefield
 IN Corrigan, Dennis, Plano, TX
 Weglein, Arthur B., Grapevine, TX
Thompson, David D., Plano, TX
 PA Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)
 PI US 5051961 19910924
 AI US 1989-427691 19891026 (7)
 DT Utility
 FS Granted
 LN.CNT 670
 INCL INCLM: 367/024.000
 INCLS: 367/057.000
 NCL NCLM: 367/024.000
 NCLS: 367/057.000
 IC [5]
 ICM: G01V001-36
 ICS: G01V001-38
 EXF 367/21; 367/24; 367/23; 367/57; 367/59; 364/421; 364/422

L2 ANSWER 66 OF 78 USPATFULL on STN

Full Text	Citing References
-----------	-------------------

AN 82:2483 USPATFULL
 TI Shoe tie stand
 IN **Thompson, David D.**, Box 122, 410 N. Race St., Princeton, IN, United States 47670
 PI US 262667 19820119
 AI US 1980-129019 19800310 (6)
 DT Design
 FS Granted
 LN.CNT 8
 INCL INCLM: D03/030.500
 INCLS: D06/085.000
 NCL NCLM: D03/200.000
 NCLS: D06/349.000; D06/410.000
 IC [1]
 ICM: D03-99
 EXF D03/30.5; D06/85; 015/265; 211/34; 211/36; 211/37; 211/38

L2 ANSWER 67 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2003:312744 USPAT2
 TI Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
 IN MacLean, David B., Providence, RI, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
 PA Pfizer Inc, New York, NY, UNITED STATES (U.S. corporation)
 PI US 6911456 B2 20050628
 AI US 2002-133006 20020426 (10)
 RLI Division of Ser. No. US 2001-803516, filed on 9 Mar 2001, Pat. No. US 6403611 Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, Pat.

No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, Pat. No. US 6107331

PRAI US 1996-13212P 19960228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2014
 INCL INCLM: 514/315.000
 INCLS: 514/428.000; 514/429.000
 NCL NCLM: 514/315.000
 NCL NCLM: 514/256.000
 NCLS: 514/428.000; 514/429.000; 514/266.200; 514/266.210; 514/307.000;
 514/314.000; 514/339.000; 514/394.000; 514/415.000
 IC [7]
 ICM: A61K031-445
 EXF 514/315; 514/428; 514/429
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 68 OF 78 USPAT2 on STN

Full Text	Citing References
AN	2003:232606 USPAT2

TI Compositions and methods for treating osteoporosis and lowering cholesterol
 IN Day, Wesley W., Old Lyme, CT, United States
 Lee, Andrew G., Old Lyme, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6756401 B2 20040629
AI US 2001-767625 20010123 (9)
PRAI US 2000-205327P 20000421 (60)
US 2000-188923P 20000126 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1547
 INCL INCLM: 514/428.000
 INCLS: 514/461.000; 514/473.000
 NCL NCLM: 514/428.000
 NCL NCLM: 514/307.000
 NCLS: 514/461.000; 514/473.000; 514/319.000; 514/408.000; 514/412.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-34
 EXF 514/317; 514/331; 514/428; 514/213; 514/423
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 69 OF 78 USPAT2 on STN

Full Text	Citing References
AN	2003:153424 USPAT2

TI Prevention of loss and restoration of bone mass by certain prostaglandin agonists
 IN Cameron, Kimberly O., East Lyme, CT, United States
 Ke, Hua Z., Ledyard, CT, United States
 Lefker, Bruce A., Gales Ferry, CT, United States
 Rosati, Robert L., Mystic, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6649657 B2 20031118
AI US 2002-256985 20020926 (10)
RLI Division of Ser. No. US 2001-897824, filed on 29 Jun 2001, now patented,

Pat. No. US 6492412 Division of Ser. No. US 331081
 PRAI WO 1997-IB1417 19971110
 US 1996-33451P 19961220 (60)
 DT Utility
 FS GRANTED
 LN.CNT 8983
 INCL INCLM: 514/545.000
 INCLS: 514/570.000; 514/461.000; 514/438.000; 560/051.000; 562/459.000;
 549/484.000; 549/070.000
 NCL NCLM: 514/545.000
 NCL NCLM: 514/227.500
 NCLS: 514/438.000; 514/461.000; 514/570.000; 549/070.000; 549/484.000;
 560/051.000; 562/459.000; 514/238.200; 514/252.100; 514/357.000;
 514/365.000; 514/385.000; 514/399.000; 514/406.000; 514/602.000;
 544/059.000; 544/159.000; 544/402.000; 546/334.000; 548/193.000;
 548/235.000; 548/335.500; 564/095.000
 IC [7]
 ICM: A61K031-235
 ICS: A61K031-34; C07C069-76; C07D307-02; C07D333-22
 EXF 560/51; 514/545; 514/570; 514/461; 514/438; 562/459; 549/484; 549/70
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 70 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2002:280644 USPAT2
 TI Methods and kits for improving vascular health
 IN Day, Wesley W., San Diego, CA, United States
 Lee, Andrew G., Old Lyme, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6620806 B2 20030916
 AI US 2001-977458 20011015 (9)
 PRAI US 2000-241532P 20001017 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2986
 INCL INCLM: 514/217.030
 INCLS: 514/212.000; 514/217.080; 514/315.000; 514/317.000; 514/323.000;
 514/307.000; 514/345.000; 514/428.000; 514/213.000; 514/582.000;
 514/585.000; 514/648.000; 514/331.000; 514/414.000; 514/415.000
 NCL NCLM: 514/217.030
 NCL NCLM: 514/266.200
 NCLS: 514/211.150; 514/217.080; 514/218.000; 514/307.000; 514/315.000;
 514/317.000; 514/323.000; 514/331.000; 514/345.000; 514/414.000;
 514/415.000; 514/428.000; 514/582.000; 514/585.000; 514/648.000;
 514/256.000; 514/266.210; 514/314.000; 514/337.000; 514/394.000
 IC [7]
 ICM: A61K031-55
 EXF 514/428; 514/320; 514/305; 514/212; 514/323; 514/414; 514/415;
 514/217.03; 514/217.08; 514/648; 514/317; 514/307; 514/315; 514/331;
 514/345; 514/213; 514/482; 514/582; 514/585
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 71 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2002:172363 USPAT2
 TI Use of estrogen antagonists and estrogen agonists in inhibiting
 pathological conditions

IN Maclean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6613796 B2 20030902
AI US 2001-999291 20011115 (9)
RLI Division of Ser. No. US 2000-511806, filed on 3 Feb 2000, now patented,
Pat. No. US 6355670 Division of Ser. No. US 1997-803733, filed on 21 Feb
1997, now patented, Pat. No. US 6107331
PRAI US 1996-13212P 19960228 (60)
DT Utility
FS GRANTED
LN.CNT 2003
INCL INCLM: 514/428.000
INCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000
NCL NCLM: 514/428.000
NCL NCLM: 514/217.010
NCLS: 514/315.000; 514/319.000; 514/343.000; 514/429.000; 514/221.000;
514/256.000; 514/266.200; 514/266.210; 514/307.000; 514/314.000
IC [7]
ICM: A61K031-40
ICS: A61K031-445; A61K031-44
EXF 514/428; 514/429; 514/343; 514/319; 514/315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 72 OF 78 USPAT2 on STN

Full Text	Citing References
--------------	----------------------

AN 2002:73008 USPAT2
TI EP4 receptor selective agonists in the treatment of osteoporosis
IN Cameron, Kimberly O., East Lyme, CT, United States
Ke, HuaZhu, Ledyard, CT, United States
Lefker, Bruce A., Gales Ferry, CT, United States
Thompson, David D., Gales Ferry, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6642266 B2 20031104
AI US 2001-991585 20011116 (9)
RLI Division of Ser. No. US 2000-738670, filed on 15 Dec 2000
PRAI US 1999-171353P 19991222 (60)
DT Utility
FS GRANTED
LN.CNT 1779
INCL INCLM: 514/424.000
INCLS: 514/381.000; 548/551.000
NCL NCLM: 514/424.000
NCL NCLM: 548/253.000
NCLS: 514/381.000; 548/551.000; 548/550.000
IC [7]
ICM: A61K031-4015
EXF 548/551; 548/253; 514/424; 514/381
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 73 OF 78 USPAT2 on STN

Full Text	Citing References
--------------	----------------------

AN 2002:27520 USPAT2
TI Prevention of loss and restoration of bone mass by certain prostaglandin
agonists
IN Cameron, Kimberly O., East Lyme, CT, United States
Ke, Hua Z., Ledyard, NY, United States
Lefker, Bruce A., Gales Ferry, CT, United States

Rosati, Robert L., Mystic, CT, United States
Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer, Inc., New York, NY, United States (U.S. corporation)
 PI US 6492412 B2 20021210
 AI US 2001-897824 20010629 (9)
 RLI Division of Ser. No. US 331081, now patented, Pat. No. US 6288120
 PRAI US 1996-33451P 19961220 (60)
 DT Utility
 FS GRANTED
 LN.CNT 9168
 INCL INCLM: 514/423.000
 INCLS: 514/448.000; 514/570.000; 514/605.000; 548/531.000; 549/072.000;
 564/099.000; 561/470.000
 NCL NCLM: 514/423.000
 NCL NCLM: 514/601.000
 NCLS: 514/252.100; 514/255.050; 514/256.000; 514/448.000; 514/570.000;
 514/605.000; 544/335.000; 544/336.000; 548/531.000; 549/072.000;
 562/470.000; 564/099.000; 514/575.000; 514/626.000; 514/665.000;
 562/623.000; 564/095.000; 564/193.000; 564/440.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-38; A61K031-19; C07D207-00; C07C303-00
 EXF 514/605; 514/570; 514/448; 514/423; 564/99; 562/470; 549/72; 548/531
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 74 OF 78 USPAT2 on STN

Full Text	Citing References
AN	2001:218612 USPAT2
TI	EP4 receptor selective agonists in the treatment of osteoporosis
IN	Cameron, Kimberly O., East Lyme, CT, United States Ke, HuaZhu, Ledyard, CT, United States Lefker, Bruce A., Gales Ferry, CT, United States Thompson, David D. , Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	<u>US 6737437</u> B2 20040518
AI	<u>US 2000-738670</u> 20001215 (9)
PRAI	<u>US 1999-171353P</u> 19991222 (60)
DT	Utility
FS	GRANTED
LN.CNT	1797
INCL	INCLM: 514/424.000
NCL	NCLM: 514/424.000
NCL	NCLM: 560/001.000
	NCLS: 548/253.000; 548/551.000
IC	[7] ICM: A61K031-40
EXF	514/424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

L2 ANSWER 75 OF 78 USPAT2 on STN

Full Text	Citing References
AN	2001:212438 USPAT2
TI	Methods of treatment for premature ejaculation in a male
IN	Lee, Andrew G., Old Lyme, CT, United States Day, Wesley W., Old Lyme, CT, United States Thompson, David D. , Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	<u>US 6512002</u> B2 20030128

AI US 2001-757423 20010110 (9)
 PRAI US 2000-175704P 20000112 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1986
 INCL INCLM: 514/427.000
 INCLS: 514/415.000; 514/410.000; 514/429.000; 514/428.000
 NCL NCLM: 514/427.000
 NCL NCLM: 514/217.030
 NCLS: 514/410.000; 514/415.000; 514/428.000; 514/429.000; 514/217.080;
 514/317.000; 514/648.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-405
 EXF 514/427; 514/428; 514/415; 514/410; 514/429
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 76 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2001:205936 USPAT2
 TI Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
 IN Paralkar, Vishwas M., Madison, CT, United States
 Thompson, David D., Gales Ferry, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6610719 B2 20030826
 AI US 2001-771164 20010129 (9)
 PRAI US 2000-178968P 20000131 (60)
 DT Utility
 FS GRANTED
 LN.CNT 743
 INCL INCLM: 514/381.000
 INCLS: 514/352.000; 514/423.000; 514/573.000; 514/530.000
 NCL NCLM: 514/381.000
 NCL NCLM: 514/381.000
 NCLS: 514/352.000; 514/423.000; 514/530.000; 514/573.000; 514/424.000
 IC [7]
 ICM: A61K031-41
 ICS: A61K031-40
 EXF 514/381; 514/382; 514/423
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 77 OF 78 USPAT2 on STN

Full Text	Citing References
-----------	-------------------

AN 2001:205925 USPAT2
 TI Compositions and methods for treating conditions responsive to estrogen
 IN Thompson, David D., Gales Ferry, CT, United States
 Lee, Andrew G., Old Lyme, CT, United States
 Day, Wesley W., Old Lyme, CT, United States
 Rosati, Robert L., Stonington, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6632834 B2 20031014
 AI US 2001-758778 20010111 (9)
 PRAI US 2000-175752P 20000112 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1958
 INCL INCLM: 514/428.000

NCL NCLM: 514/428.000
 NCL NCLM: 514/317.000
 NCLS: 514/308.000; 514/408.000
 IC [7]
 ICM: A61K031-40
 EXF 514/428
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 78 OF 78 USPAT2 on STN

Full Text	Citing References
AN	2001:145314 USPAT2
TI	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
IN	Maclean, David B., Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PA	Pfizer Inc., New York, NY, United States (U.S. corporation)
PI	US 6403611 B2 20020611
AI	US 2001-803516 20010309 (9)
RLI	Continuation of Ser. No. <u>US 1999-314758</u> , filed on 19 May 1999, now patented, Pat. No. <u>US 6274618</u> Continuation of Ser. No. <u>US 1997-803733</u> , filed on 21 Feb 1997, now patented, Pat. No. <u>US 6107331</u>
PRAI	US 1996-13212P 19960228 (60)
DT	Utility
FS	GRANTED
LN.CNT	2014
INCL	INCLM: 514/315.000 INCLS: 514/428.000; 514/429.000
NCL	NCLM: 514/315.000
NCL	NCLM: 514/428.000 NCLS: 514/428.000; 514/429.000; 514/304.000; 514/320.000
IC	[7] ICM: A61K031-445
EXF	514/429; 514/428; 514/315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

=> d his full.

(FILE 'HOME' ENTERED AT 18:58:50 ON 10 AUG 2005)

FILE 'USPATFULL, USPAT2' ENTERED AT 18:59:06 ON 10 AUG 2005

E MACLEAN D/IN
 L1 26 SEA "MACLEAN DAVID B"/IN
 D 1-26
 E THOMPSON D/IN
 L2 78 SEA "THOMPSON DAVID D"/IN
 D 1-78

FILE HOME

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Aug 2005 (20050809/PD)
 FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)
 HIGHEST GRANTED PATENT NUMBER: US6928656
 HIGHEST APPLICATION PUBLICATION NUMBER: US2005172377
 CA INDEXING IS CURRENT THROUGH 9 Aug 2005 (20050809/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Aug 2005 (20050809/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

```

>>> USPAT2 is now available.  USPATFULL contains full text of the    <<<
>>> original, i.e., the earliest published granted patents or        <<<
>>> applications.  USPAT2 contains full text of the latest US        <<<
>>> publications, starting in 2001, for the inventions covered in     <<<
>>> USPATFULL.  A USPATFULL record contains not only the original    <<<
>>> published document but also a list of any subsequent              <<<
>>> publications.  The publication number, patent kind code, and      <<<
>>> publication date for all the US publications for an invention    <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.                                                         <<<

```

```

>>> USPATFULL and USPAT2 can be accessed and searched together      <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to        <<<
>>> enter this cluster.                                             <<<
>>>                                                                    <<<
>>> Use USPATALL when searching terms such as patent assignees,     <<<
>>> classifications, or claims, that may potentially change from    <<<
>>> the earliest to the latest publication.                         <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPAT2

```

FILE COVERS 2001 TO PUBLICATION DATE: 9 Aug 2005 (20050809/PD)
FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)
HIGHEST GRANTED PATENT NUMBER: US2004208056
HIGHEST APPLICATION PUBLICATION NUMBER: US2005172357
CA INDEXING IS CURRENT THROUGH 9 Aug 2005 (20050809/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Aug 2005 (20050809/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

```

USPAT2 is a companion file to USPATFULL. USPAT2 contains full text of the latest US publications, starting in 2001, for the inventions covered in USPATFULL. USPATFULL contains full text of the original published US patents from 1971 to date and the original applications from 2001. In addition, a USPATFULL record for an invention contains a complete list of publications that may be searched in standard search fields, e.g., /PN, /PK, etc.

USPATFULL and USPAT2 can be accessed and searched together through the new cluster USPATALL. Type FILE USPATALL to enter this cluster.

Use USPATALL when searching terms such as patent assignees, classifications, or claims, that may potentially change from the earliest to the latest publication.

=>